Please login to the form below

Not currently logged in
Email:
Password:

China recalls GSK antibiotic

Chinese authorities have recalled GlaxoSmithKline's antibiotic Augmentin after traces of a compound used to make plastics more flexible were found in the treatment's syrup form

Chinese authorities have recalled GlaxoSmithKline's (GSK) antibiotic Augmentin (amoxicillin and clavulanate potassium) after traces of a compound used to make plastics more flexible were found in the treatment's syrup form.

Test results have shown the plasticiser diisodecyl phthalate (DIDP) is present in the antibiotic, according to China's State Food and Drug Administration. DIDP is banned in the production of medicines.

GSK has been ordered to immediately suspend sales of the product, which is regularly used to treat infections in children.

As reported in the UK's Daily Telegraph, a GSK spokesperson said: "GSK is currently in discussion with a number of regulatory agencies in the Asia Pacific region, some of whom have also conducted tests."

"The amount of phthalates identified as present in Augmentin syrup samples tested is very low; some tests have found none and the highest level reported by the authorities is 88 parts per million. Even this highest result is significantly lower than the levels that the US and European authorities deem as presenting no risk to humans."

Taiwan and Hong Kong had previously demanded GSK recall Augmentin after it was found to contain DIPD.

21st June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics